SAN DIEGO--(BUSINESS WIRE)--Innovus Pharmaceuticals, Inc. ("Innovus Pharma") (OTCQB Venture Market: INNV), an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases, announced today that it received the CPNP notification number required to commercialize Zestra Glide® in all 28 member countries of the European Union. This represents the third Innovus Pharma product to receive CPNP notification in the European Union in the last two months, the others being for Zestra® and Sensum+®.
“We are pleased to expand the commercialization market for Zestra Glide® to the European Union,” said Innovus Pharma CEO Dr. Bassam Damaj. “Combined with our recent announcements of notifications to commercialize Zestra® and Sensum+® in the EU, we are excited to offer these three additional products to potential partners in the region to help us expand Innovus Pharma’s product sales in this, the second largest market in the world.”
Zestra Glide® is currently exclusively partnered with Orimed Pharma in Canada, Sothema Labs in the Middle East and North Africa, Elis Pharma in Turkey and certain select markets, Oz Biogenics in Myanmar and Vietnam, and KLabs in India.
Zestra Glide® is currently approved in 32 countries and marketed and sold in three countries, including the United States, Canada and Morocco.
About Zestra Glide® and the Lubricant Market
Zestra Glide® is the only water-based clinically tested lubricant with high viscosity. Increased viscosity usually translates into longer effects. The lubricant market is estimated to be around $200 million in the U.S. (Symphony IRI Group Study, 2012).
About Innovus Pharmaceuticals, Inc.
Headquartered in San Diego, Innovus Pharma is an emerging over-the-counter (“OTC”) consumer goods and specialty pharmaceutical company engaged in the commercialization, licensing and development of safe and effective non-prescription medicine and consumer care products to improve men’s and women’s health and vitality and respiratory diseases. Innovus Pharma delivers innovative and uniquely presented and packaged health solutions through its (a) OTC medicines and consumer and health products, which the Company markets directly; (b) commercial partners to primary care physicians, urologists, gynecologists and therapists; and (c) directly to consumers through its on-line channels, retailers and wholesalers. The Company is dedicated to being a leader in developing and marketing new OTC and branded Abbreviated New Drug Application (“ANDA”) products. The Company is actively pursuing opportunities where existing prescription drugs have recently, or are expected to, change from prescription (or Rx) to OTC.
For more information, go to www.innovuspharma.com; www.zestra.com; www.ejectdelay.com; www.myvesele.com; www.sensumplus.com; www.myandroferti.com; www.beyondhumantestosterone.com; www.getbeyondhuman.com; www.trybeyondhuman.com; www.recalmax.com; www.urivarx.com
Innovus Pharma's Forward-Looking Safe Harbor:
Statements under the Private Securities Litigation Reform Act, as amended: with the exception of the historical information contained in this release, the matters described herein contain forward-looking statements that involve risks and uncertainties that may individually or mutually impact the matters herein described for a variety of reasons that are outside the control of the Company, including, but not limited to, projected revenues from the sale of the Zestra Glide® product in Europe, the sale of other of the Company’s products, projected online subscribers, estimated market for its products, and statements about achieving its other development, growth, commercialization, financial and staffing objectives. Readers are cautioned not to place undue reliance on these forward-looking statements as actual results could differ materially from the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's most recent filing on Form S-1, annual report on Form 10-K, and other filings made with the SEC. Copies of these reports are available from the SEC's website or without charge from the Company.